Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides healthcare research services. Valued at $30.3 billion by market cap, the company provides analytics, technology solutions, and clinical research services to the life sciences industry that help them in the clinical development and commercialization of medical therapies that improve healthcare outcomes for patients.
Companies valued at $10 billion or more are generally described as “large-cap stocks,” and IQV fits that description perfectly, with its market cap exceeding that mark, indicating its size, influence, and dominance in the diagnostics and research industry. With strong revenue growth and a global presence in more than 100 countries, IQVIA’s expertise and scale provide a competitive edge that is hard to match.
Despite its considerable strength, IQV is down 27.7% from the 52-week high of $247.05 reached on January 9. Over the past three months, IQV stock has fallen 18.1%, dwarfing the Nasdaq Composite’s ($NASX) 3.7% loss over the same time frame.
IQV shares are down 20.8% on a YTD basis and down 6.8% over the past 52 weeks, significantly underperforming the NASX’s 2.4% YTD loss and 24.7% return over the past year.
Confirming the bearish trend, IQV has been trading below the 50-day and 200-day moving averages since early February, with little change.
IQVIA’s poor performance was driven by margin compression and concerns about earnings sustainability. Additionally, acquisitions expanded capabilities, but operating margins declined due to revenue growth and product mix changes.
On February 5, IQV shares fell 10.7% after reporting Q4 results. Adjusted EPS of $3.42 beat Wall Street expectations of $3.40. The company’s revenue was $4.4 billion, beating Wall Street forecasts of $4.2 billion. IQV expects full-year adjusted EPS of $12.55 to $12.85, and revenue of $17.2 billion to $17.4 billion.
In the competitive field of diagnostics and research, Agilent Technologies, Inc. (A) leads against IQV, showing volatility with a loss of 14.3% on a YTD basis, but lags behind the stock with a decline of 7.9% over the past 52 weeks.
